https://www.selleckchem.com/pr....oducts/SB-203580.htm
One patient in both groups died from metastatic disease. Overall-survival at 2 and 5 years was 91,7% and 82,4% in the AS-group vs. 96,5% and 96,5% in the PCA-group (p=0,113). Failure-free survival at 2 and 5 years was 90,9% and 70,1% in the AS-group vs. 93,1% and 70,9% in the PCA-group (p=0,645). AS and PCA provide similar survival outcomes and are safe and valid treatment options for elderly and comorbid patients with SRMs. AS and PCA provide similar survival outcomes and are safe and valid treatment options for elderly and comorbid
Like
Comment
Share
